MCK Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
McKesson Corp (MCK) is a good buy for a beginner investor with a long-term investment strategy and $50,000-$100,000 available. The stock shows strong financial performance, positive analyst sentiment, and bullish technical indicators. Additionally, Congress members have shown confidence in the stock with recent purchases, and options data reflects a bullish sentiment.
The technical indicators are bullish. The MACD is positive and expanding, the RSI is in the neutral zone at 74.203, and the moving averages are bullish (SMA_5 > SMA_20 > SMA_200). The stock is trading near its resistance level (R1: 971.307) but has room to move towards R2: 990.82.
Strong financial performance in Q3 2026 with revenue up 11.40% YoY, net income up 34.93% YoY, and EPS up 38.18% YoY.
Positive analyst sentiment with multiple price target increases and 'Buy' or 'Overweight' ratings.
Congress members have shown confidence with 4 recent purchase transactions.
Bullish technical indicators and options sentiment.
Insider selling has increased significantly (389.92% over the last month).
The stock is trading at a 15% premium to its three-year average, which may limit upside potential in the short term.
McKesson delivered strong Q3 2026 results with revenue of $106.16 billion (up 11.40% YoY), net income of $1.186 billion (up 34.93% YoY), and EPS of $9.59 (up 38.18% YoY). Gross margin also improved to 3.46% (up 1.47% YoY).
Analysts are overwhelmingly positive on McKesson. Recent upgrades include Barclays raising the price target to $1,050, JPMorgan to $1,107, and TD Cowen to $1,012. The stock is rated 'Buy' or 'Overweight' by most analysts, reflecting confidence in its performance and safety within the healthcare sector.
